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Increase Prefrontal Cortical Neuronal Responsiveness
David M. Devilbiss1 and Craig W. Berridge1,2
1 Department of Psychology, University of Wisconsin, Madison, WI 53706
2 Department of Psychiatry, University of Wisconsin, Madison, WI 53706
Abstract
Background—Despite widespread use of low-dose psychostimulants for the treatment of attention
deficit hyperactivity disorder (ADHD), the neural basis for the therapeutic actions of these drugs are
not well-understood. We recently demonstrated that low-dose methylphenidate (MPH) increases
catecholamine efflux preferentially within the prefrontal cortex (PFC), suggesting the PFC is a
principal site of action in the behavioral-calming and cognition-enhancing effects of low-dose
psychostimulants. To better understand the neural mechanisms involved in the behavioral actions of
low-dose stimulants, the current study examined the effects of low-dose MPH on the discharge
properties of individual and ensembles of PFC neurons.
Methods—Extracellular activity of multiple individual PFC neurons was recorded in freely moving
rats using multi-channel recording techniques. Behavioral studies identified optimal, working
memory-enhancing doses of intraperitoneal MPH. The effects of these low-doses of MPH on PFC
neuronal discharge properties were compared to: 1) the effects of high-dose MPH on PFC neuronal
discharge; 2) the effects of low-dose MPH on neuronal discharge within the somatosensory cortex.
Results—Only working memory-enhancing doses of MPH increased the responsivity of individual
PFC neurons and altered neuronal ensemble responses within the PFC. These effects were not
observed outside the PFC (i.e. within somatosensory cortex). In contrast, high-dose MPH profoundly
suppressed evoked discharge of PFC neurons.
Conclusions—These observations suggest that preferential enhancement of signal processing
within the PFC, including alterations in the discharge properties of individual PFC neurons and PFC
neuronal ensembles, underlie the behavioral/cognitive actions of low-dose psychostimulants.
Keywords
Psychostimulants; ADHD; Dopamine; Norepinephrine; Attention; Working Memory; Principal
component analysis; Multi-channel recording; Prefrontal cortex
Methylphenidate (MPH; Ritalin®) and other psychostimulants, are used extensively in the
treatment of attention deficit/hyperactivity disorder (ADHD; see review 23,44). Importantly,
low doses of these drugs exert behavioral-calming and cognition-enhancing actions in normal
human and animal subjects (6,10,30,32,33,35,40). These effects are in contrast to the
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locomotor-activating and cognition-impairing actions of higher doses of these drugs (31,37).
Given their widespread use, it is surprising that the neural mechanisms involved in the
behavioral/cognitive actions of low-dose psychostimulants remain poorly understood
The prefrontal cortex (PFC) plays a critical role in the regulation of higher cognitive function,
impulsivity and behavioral activity (for review: 7). Thus, it is of interest that low and cognition-
enhancing doses of MPH increase extracellular levels of catecholamines preferentially within
the PFC (10,22,29,30). These observations are consistent with evidence implicating PFC
dysfunction in the neuropathology of ADHD (2,14,40). Combined, these observations suggest
that the cognition-enhancing and therapeutic actions of low-dose stimulants involve the
modulation of PFC neuronal function. However, currently the nature of these modulatory
actions is unclear.
The current studies were designed to better understand the impact of low-dose
psychostimulants on PFC circuit function. Behavioral studies first determined the degree to
which low-dose intraperitoneal (IP) MPH affects PFC-dependent spatial working memory in
rats, identifying a dose range that produced an inverted-U shaped facilitation/impairment.
Subsequent studies determined the effects of these low-doses of MPH, as well as a higher and
behaviorally-activating dose, on spontaneous and evoked discharge of individual neurons and
neuronal ensembles within the PFC of unanesthetized rats. Further studies compared the effects
of a cognition-enhancing dose of MPH on PFC neuronal discharge to actions of this dose on
neuronal activity within the somatosensory cortex.
Results obtained indicate that the behavioral-calming and cognition-enhancing actions of low-
dose psychostimulants involve a selective enhancement in the signal processing abilities of
PFC neurons and alterations in the distributed representation of afferent input within the PFC.
These actions contrast with the profound suppression of PFC neuronal responsivity by higher
doses of MPH associated with behavioral activation and cognitive impairment. Combined,
these observations provide novel insight into the neural mechanisms and circuitry associated
with the therapeutic actions of low-dose psychostimulants.
Experimental Procedures
Animals
Male Sprague–Dawley rats (300–450 g; Charles River, Wilmington, MA) were singly-housed
on a 13-h/11-h light/dark cycle and provided ad lib access to food and water. All procedures
were in accordance with NIH guidelines and were approved by the University of Wisconsin
Institutional Animal Care and Use Committee.
Drugs
MPH (Sigma Chemical Co., Saint Louis, MO) was dissolved in 0.9% saline. The temporal
resolution of intraperitoneal (IP) drug delivery is superior over oral administration and thus
was viewed as preferable for the current electrophysiological studies. Previous studies
demonstrated that 2.0 mg/kg orally-administered and 0.5 mg/kg IP-administered MPH are
equipotent in terms of plasma levels and effects on catecholamine efflux (10). In these studies,
2.0 mg/kg oral, but not 8.0 mg/kg, MPH improved working memory. Thus, the current studies
examined the behavioral and electrophysiological effects of IP-administered MPH at 0.25 mg/
kg, 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg as well as a substantially higher dose of 15.0 mg/kg.
Spatial working memory testing
Animals (n=15) were trained and tested in a T-maze-based delayed alternation task of spatial
working memory similar to that described previously (10). Animals were rewarded when they
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entered the maze arm not chosen on the previous trial. A delay between trials was adjusted
until performance was stable and within the range of 60–80% (range=10–100 secs). Stable
performance was defined as two consecutive days in which performance did not differ by more
than 10%. Animals were administered vehicle or MPH 20-minutes prior to testing. Changes
in the correct number of trials were analyzed using a repeated-measures (dose) ANOVA. Post-
hoc comparisons were performed using the Fisher LSD test.
Electrophysiological Recordings
Surgery—Animals (n=13) were implanted with microelectrode arrays (SB103, NB Labs,
Dennison, TX) into the PFC (A+3.2, L±1.2; V−3.0) and a stimulation electrode (SNEX100-15,
David Kopf, Tujunga, CA) into the CA1-subiculum region of the hippocampus (A−6.72, L
±5.5, V−6.5). PFC microelectrode arrays were oriented in a rostral-caudal direction targeting
the prelimbic subregion (layers III–V; Figure 1a–b). Additionally, two animals were implanted
with microelectrode arrays into the barrel field (BF) somatosensory cortex (A−2.5, L±5.8, V
−1.2) and a stimulating electrode around a single vibrissa (C3) of the whisker pad. BF cortex
arrays were implanted such that with a rostral-caudal orientation, the majority of
microelectrodes were in layers II/III–V of the C3 barrel (Figure 1c). Halothane anesthesia
(Halocarbon Laboratories, River Edge, NJ; 1–4% in air) was used for PFC implants and chloral
hydrate (390 mg/kg; Sigma, St. Louis, MO)-pentobarbital (25 mg/kg; Abbot Laboratories,
North Chicago, IL) was used for BF cortex implants. Electrodes were attached to the skull with
dental acrylic (Plastics One, Roanoke, VA) and animals were allowed to recover for 5–10 days.
Following each experiment, electrode placements were marked and examined in ferrocyanide-
reacted, counter-stained sections (Figure 1; and 19).
Recording sessions—Animals were tested and videotaped in sound-attenuating chambers
(9), provided ad lib access to food and water, and habituated to the experimental procedure for
at least two hours prior to experimentation. Multi-channel electrophysiological hardware and
software (RASPUTIN, Plexon Inc, Dallas, TX) were used to record EEG (surface-depth) and
simultaneously amplify, discriminate, and record action potential waveforms from putative
single neurons (“units”) of the PFC or BF cortex, as previously described (19). During
habituation to the chamber, repeated uniform biphasic current pulses were delivered through
the CA1-subiculum or whisker pad electrodes and adjusted to elicit stimulus-evoked responses
from at least 25% of the recorded units.
Baseline neuronal discharge/responsivity was recorded for 60-minutes in 15-minute blocks,
each comprised of 5-minutes of spontaneous discharge followed by 10-mintues of stimulation
of the CA1-subiculum (0.3–1.2 μA @ 0.25 Hz × 10-minutes=150 stimulations) or whisker pad
(0.5–3 mA @ 0.5 Hz, 1 ms duration × 10-minutes=300 stimulations). Vehicle or MPH (0.25,
0.5, 1.0, 2.0, or 15.0 mg/kg) was administered IP following baseline recording. Spontaneous
and stimulus-evoked PFC/BF cortex activity was then assessed in 15-minute blocks for the
subsequent 90–180 minutes.
Analysis of electrophysiological data—The effects of MPH on EEG and the magnitude
and timing of stimulation-evoked discharge were analyzed similar to that described previously
(11,19,20). EEG (0.7–170 Hz; 1.0 kHz sample rate) recorded from the PFC or BF cortex was
hand-scored off-line for desynchronized and slow-wave (≥2x desynchronous voltage) activity
(see: 11). EEG analyses were used to assess 1) wake-promoting actions of MPH and 2) control
for potential effects of fluctuations in sleep-wake state on the activity/reactivity of cortical
neurons. Video-recordings confirmed that the majority of desynchronized activity was
associated with waking. All electrophysiological analyses were limited to periods of
nonsynchronous EEG. Criteria used to verify that individual waveforms originated from a
single neuron (19,20) included characterization of: 1) waveform peak voltage, 2) waveform
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slope(s), 3) scattergram of the first two principal components of the action-potential’s sampled
voltages, and 4) spike train auto-correlegram (19 see also: 20).
Stimulus-evoked discharge patterns of individual neurons were analyzed by quantifying peri-
stimulus time histograms (PSTH) generated from equal numbers of randomly selected stimulus
presentations during baseline and post-treatment periods (1di–iii; 19 and also: 15–17,20).
Excitatory response windows were defined by sustained discharge rates exceeding 3 SD of
spontaneous discharge. The peak response (peak–pre-stimulus average) and latency-to-peak
that occurred within the excitatory window was determined. Stimulus-evoked inhibition or
post-excitatory inhibition windows were defined by a 1 SD reduction in spontaneous discharge.
Both the magnitude (pre-stimulus average–inhibition) and duration of inhibition were
quantified. Treatment-induced changes in these measures were represented as percent change
from baseline. In a number of cases, evoked-responses were initially absent or minimal during
baseline recordings (< 3 SD above spontaneous rates), but became prominent and achieved
significance following treatment; this modulatory action was classified as “gating”.
Discharge pattern relationships between many simultaneously recorded PFC neurons were also
examined using principal component analysis (PCA). PCA eigenfunctions were generated by
first decomposing the individual spike trains by PCA using correlation matrixes and varimax
rotations as previously described (16 see also: 15,17,20). Second, individual spike trains were
weighted with eigenvalues generated by PCA decomposition, summed across neurons, and
plotted as a PSTH. The post-stimulus eigenfunction excitatory peak height was calculated for
PC1, whereas peak-to-trough distance was determined for PC2. Differences in PCA
eigenfunctions before and after treatments were analyzed to determine whether MPH produces
an alteration in the distributed activity of an ensemble of simultaneously recorded PFC neurons
(17).
Data were analyzed using a mixed two-way repeated-measures ANOVA (time, treatment).
Post-hoc comparisons were performed using the Fisher LSD test.
RESULTS
Effects of IP MPH on Spatial Working Memory
The effects of IP administered low-dose MPH (vehicle, n=12; 0.5 mg/kg, n=12; and 2.0 mg/
kg, n=8) on performance in a spatial working memory task were first examined. IP MPH
produced an inverted-U shaped dose-dependent facilitation of working memory (dose,
F(2,32)=9.882, p=0.001): 0.5 mg/kg MPH improved whereas 2.0 mg/kg impaired performance
(Figure 2). Based on these observations, we examined the effects of varying doses of IP MPH
on PFC neuronal discharge activity, including doses that spanned the range associated with
cognition enhancement (0.25, 0.5, 1.0 and 2.0 mg/kg) as well as a higher dose that produced
robust locomotor activation and stereotypy (15.0 mg/kg).
Effects of MPH on EEG activity state
EEG-activating effects of MPH were analyzed for all animals used in the PFC recording studies
(n=13). MPH dose-dependently affected the duration of desynchronized (low-voltage, high-
frequency) EEG activity (dose, F(5,43)=16.0, p < 0.001; time, F(3,129)=7.9, p < 0.001;
dose×time, F(15,129)=1.71, p=0.056). The lowest doses of MPH (0.25, 0.5, and 1.0 mg/kg)
lacked arousal-promoting actions (Figure 3). 2.0 mg/kg MPH produced a modest though
statistically-significant increase in the duration of desynchronized EEG that was not
accompanied by an increase in locomotor activity beyond that associated with normal waking
(data not shown). In contrast, the highest dose tested (15.0 mg/kg) produced a robust EEG
activation accompanied by locomotor activation and stereotypy (repetitive sniffing, head
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movements and licking; data not shown) typical of high-dose stimulants (28). For these and
all subsequent analyses, the 1.0 mg/kg dose produced an effect in between that observed with
the 0.5 mg/kg and 2.0 mg/kg doses. To improve readability of Figure 3 and all subsequent
figures, data for the 1.0 mg/kg dose are not plotted.
Effects of MPH on spontaneous neuronal discharge within the PFC
The baseline mean spontaneous discharge rate of PFC neurons was 0.84±0.11 Hz (SEM).
ANOVA indicated a significant effect of MPH on spontaneous discharge rate of PFC neurons
(dose, F(5,885)=2.02, p=0.073; time, F(2,1770)=6.824, p=0.0011; dose×time, F(10,1770)=5.249,
p < 0.001). Post-hoc analyses indicated that the lowest doses of MPH (0.25–2.0 mg/kg)
produced a modest increase in spontaneous discharge rates of PFC neurons (Figure 4). The
largest increase occurred with the lowest dose examined (0.25 mg/kg) and was confined to the
later portion of the recording session (i.e. 1.22-fold above baseline during the 60–90 minute
post-treatment epoch; see Figure 4). In contrast, 15.0 mg/kg MPH modestly reduced
spontaneous discharge rates of PFC neurons (1.32-fold reduction) in the 30–90 minutes post-
treatment epochs.
Effects of MPH on evoked discharge within the PFC
Neurons that were excited by CA1-subiculum stimulation during baseline conditions (24% of
recorded neurons, Table 1), responded with an average evoked response of 5.53±0.78 Hz. This
relatively modest response indicates stimulation intensities were relatively low and close to
threshold for evoking excitatory discharge. MPH produced dose-dependent alterations in
evoked discharge of PFC neurons that followed an inverted-U dose-response curve (Figure 5a;
dose, F(5,176)=3.325, p=0.0067; time, F(2,352)=0.631; dose×time, F(10,352)=0.391). Thus, lower
doses of MPH (0.25–0.5 mg/kg) facilitated excitatory evoked-responses (1.58-fold; e.g. Fig.
1D1), while increasing doses no longer facilitated (1.0 mg/kg) and then suppressed evoked
discharge (2.0 and 15.0 mg/kg).
Beyond the net facilitatory effect of low-dose MPH on excitatory responses, low-dose MPH
(0.5 mg/kg, 1.0 mg/kg) also produced a substantial ‘gating’ effect (Fig. 1D2 and Table 2; Chi-
Square: 0.5, p=0.0187; 1.0, p=0.0568 compared to saline). Gating is characterized as the
emergence of robust stimulus-evoked discharge to previously subthreshold excitatory input
(see: 43 and Methods). Thus, cognition-enhancing doses of MPH increase both the magnitude
of the excitatory response of individual PFC neurons and the number of PFC neurons
responding to excitatory input.
The latency-to-peak stimulus-evoked excitatory discharge was 38.8±9.1 ms for CA1-
subiculum stimulation responsive neurons. Low-dose MPH had minimal effects on the latency-
to-peak stimulus-evoked discharge (Figure 5b; dose, F(5,90)=3.069, p=0.0133; time,
F(2,180)=0.721; dose×time, F(10,180)=1.040). Only the highest dose of MPH (15.0 mg/kg)
produced a small (0.07-fold), but significant, increase in peak latency.
Effects of MPH on evoked inhibition within the PFC
CA1-subiculum stimulation evoked an inhibitory response in a relatively large subset of PFC
neurons (41% of recorded neurons; Table 1 and Fig. 1D1). Stimulus-evoked inhibition was
either observed in the absence of an evoked excitatory response or as part of a biphasic
excitatory-inhibitory response. Evoked inhibition was characterized by a decrease in
spontaneous discharge rate from 0.84±0.11 Hz to 0.14±0.04 Hz with a duration of 727±64 ms.
Stimulus-induced inhibition of PFC neurons was significantly altered by MPH (Figure 6a;
dose, F(5,376)=3.66, p=0.003; time, F(2,752)=0.365; dose×time, F(10,752)=1.36). Low-dose MPH
(0.5 mg/kg) increased the magnitude of inhibitory responses 1.54-fold (more inhibition) during
the first 30 minute post-treatment epoch, whereas 2.0 mg/kg MPH did not significantly affect
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the inhibitory response magnitude. At the highest dose (15.0 mg/kg), MPH decreased the
magnitude of the inhibitory response 1.81-fold (less inhibition). Decreases in inhibition
observed at this dose in part stems from MPH-induced decreases in spontaneous discharge (see
above).
The duration of inhibition was also significantly effected by MPH (dose, F(5,375)=3.334,
p=0.006; time, F(2,750)=0.224; dose×time, F(10,750)=0.778). Low-dose MPH (0.25–0.5 mg/kg)
reduced the duration of inhibition, with a maximal effect (1.28-fold reduction) observed
following 0.5 mg/kg (Figure 6b). Higher doses of MPH (2.0–15.0 mg/kg) did not significantly
affect duration of the inhibitory response. Thus, only at a low and cognition-enhancing dose
(0.5 mg/kg), MPH simultaneously increased the magnitude of inhibitory responses of PFC
neurons while decreasing the duration of these inhibitory responses.
Effects of MPH on distributed activity of ensembles of PFC neurons
Distributed patterns of activity across ensembles of interconnected neurons likely represent
additional levels of information coding beyond discharge rates and patterns of individual
neurons (15 see also: 8,16,17,19,20,25–27,39). Principal component analysis (PCA) identifies
correlated activity across spike trains of an ensemble of neurons, with each increasing
component accounting for residual correlated activity from the previous component. Figure 7
plots the first two PCA eigenvectors derived from these analyses. As shown in Figure 7a,
punctate CA1-subiculum stimulation produced an upward deflection in the first PC
eigenfunction (PC1). MPH produced an inverted-U dose-dependent increase in the post-
stimulus peak of activity of PC1 (dose, F(5,81)=2.785, p=0.049; time, F(2,36)=2.01; dose×time,
F(10,36)=0.22), with the 0.5 mg/kg dose maximally increasing PC1 6.7-fold (Figure 7b). In
contrast, CA1-subiculum stimulation elicited a biphasic response from the second PC
eigenfunction (PC2). MPH significantly affected the response of PC2 (dose, F(5,16)=5.266,
p=0.005; time, F(2,32)=3.607, p=0.038; dose×time, F(10,32)=1.727). Across the lowest doses
tested (0.25–0.5 mg/kg), MPH dose-dependently reduced the magnitude of PC2 (Figure 7d),
with a maximal reduction (6.8-fold) at 0.5 mg/kg. These analyses indicate that low-dose MPH
alters the relationships between neuron activity patterns across an ensemble of PFC neurons
in a non-uniform manner (i.e. decreased PC2, increased PC1) suggesting a reduction in the
complexity of distributed neuronal discharge within the PFC.
Effects of MPH on spontaneous and stimulus-evoked neuronal discharge within the
somatosensory barrel field (BF) cortex
Limited additional studies examined the effects of 0.5 mg/kg MPH on the activity of
somatosensory BF cortical neurons. BF cortical neurons responded to stimulation of the rat’s
whisker pad similar to that previously described (20,22). During baseline, BF cortical neurons
exhibited a mean spontaneous discharge of 2.08±0.34 Hz (SEM), mean sensory-evoked
discharge of 35.7±3.8 Hz, and a mean latency-to-peak stimulus-evoked excitatory discharge
of 7.66±0.4 ms. MPH (0.5 mg/kg) did not significantly affect spontaneous discharge (Figure
8a; time, F(3,60)=1.40) or either the magnitude (Figure 8b; time, F(3,46)=0.16) or latency-to-
peak stimulus-evoked excitatory discharge (Figure 8c; time, F(3,46)=0.01).
Discussion
The current study provides the first demonstration of a close relationship between the
cognition-enhancing actions of low-dose psychostimulants and drug-induced increases in
responsivity of individual PFC neurons and PFC neuronal ensembles. Facilitation of PFC
neuronal responsiveness (both excitatory and inhibitory) and increases in the response of highly
correlated activity distributed across neural ensembles (PC1) were observed only following
low and clinically-relevant doses of MPH that lack EEG- and locomotor-activating effects and
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improve PFC-dependent cognition. Low-dose MPH-induced alterations in PFC neuronal
responsiveness were associated with relatively minimal change in the spontaneous discharge
activity of PFC neurons. Modestly higher doses of MPH that also lacked locomotor-activating
effects, but impaired PFC-dependent cognition, had minimal effects on PFC neuronal discharge
properties. In contrast to that seen with low-dose MPH, a locomotor-activating/stereotypy-
inducing dose of MPH potently suppressed evoked discharge of individual PFC neurons and
modestly suppressed spontaneous discharge. Importantly, low-dose MPH-induced facilitation
of neuronal responsivity was selective to the PFC and was not observed in the somatosensory
cortex. These observations suggest that the cognition-enhancing actions of low-dose
psychostimulants involve the selective enhancement of information processing within the PFC
via actions at both the single neuron and neuronal ensemble levels.
Clinically-relevant doses of MPH preferentially impact the PFC
Low-doses of psychostimulants improve PFC-dependent working memory and other cognitive
processes while suppressing impulsivity and locomotor activity. Importantly, these actions are
not confined to ADHD and are observed in normal human and animal subjects (6,10,30,32,
33,35,36,40). The current studies demonstrate that stimulant-induced facilitation of PFC-
dependent cognition is not dependent on the oral route of administration, when doses are
adjusted to yield comparable and clinically-relevant plasma concentrations (10).
Despite widespread clinical use of psychostimulants, the neural mechanisms responsible for
their cognition-enhancing/behavioral-calming actions are poorly understood. Imaging studies
implicate PFC dysfunction in ADHD (14,40). Moreover, lesions of the PFC or PFC-
catecholamine fibers result in behavioral attributes similar to those seen in ADHD, including
attentional deficits and hyperactivity (for review: 4). Recent microdialysis studies demonstrate
that clinically-relevant doses of MPH increase NE and DA efflux preferentially within the PFC
(10,22,29,30). The current studies further indicate that, only at these low and cognition-
enhancing doses, MPH increases evoked responding of PFC neurons and enhances highly
correlated discharge-pattern relationships between neurons of the PFC. The facilitatory action
of low-dose MPH on PFC neuronal responsivity contrasts with the profound suppression of
evoked discharge observed at higher doses and the minimal effects of low-dose MPH on evoked
discharge of somatosensory cortical neurons (see: 22). Combined, these studies indicate a
unique sensitivity of the PFC to low-dose MPH. This sensitivity is likely a critical factor in the
therapeutic actions of low-dose psychostimulants.
It is important to note this hypothesis does not imply that all behavioral/therapeutic effects of
low-dose stimulants are dependent on actions within the PFC (see: 21). In particular, stimulant
actions outside the PFC may be of greater relevance in patients requiring higher doses of
psychostimulants for therapeutic efficacy, given the more widespread actions of MPH on
catecholamine efflux with increasing dose (10,22).
Functional relevance of MPH-induced changes in signal processing within the PFC: single
unit observations
The current study demonstrates that cognition-enhancing doses of MPH increase the magnitude
of both excitatory and inhibitory responses of PFC neurons while simultaneously reducing the
duration of the inhibitory response. Low-dose MPH also produced ‘gating’, resulting in a larger
number of PFC neurons responsive to CA1-subiculum input. Combined, these observations
suggest low-dose MPH increases both the sensitivity of PFC neurons and the pool of responsive
PFC neurons in a more complex manner than simply regulating the level of PFC excitability
(i.e. gain of neuronal activity), consistent with known actions of catecholamines on cortical
neurons (4,6,18,34,38,45,46).
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High doses of MPH, associated with locomotor activation and stereotypy, modestly suppressed
spontaneous discharge, consistent with previous observations with amphetamine (24). In
contrast, high-dose MPH produced a profound suppression of evoked responses, essentially
rendering the PFC non-responsive and functionally taking it “off-line”. It is likely that these
actions contribute to the cognition-impairing and behaviorally-activating actions of high-dose
psychostimulants (31,37).
Functional relevance of MPH-induced changes in signal processing within the PFC:
Ensemble observations
Information from the hippocampus to the PFC is likely in the form of a sparse and distributed
code (8,25–27,39). Given this, it is of particular interest that low and cognition-improving
doses of MPH substantially altered the distributed representation of PFC responses to
hippocampal afferent input: simultaneously enhancing PC1 while suppressing PC2. In contrast
to that of sensory systems (16), the functional significance of PC1 and PC2 derived from PFC
neuron recordings is currently unclear. Nonetheless, these observations suggest that low-dose
MPH alters the relationship of firing patterns within a population of PFC neurons, reorganizing
the representation of afferent input within this population of neurons. This may, in part, involve
an increase in the pool of responsive neurons (gating) observed with these doses of MPH.
Functionally these actions may suggest that, within the PFC dominant signals (PC1) are
enhanced while less redundant information (i.e. potential noise, PC2) is suppressed following
low-dose MPH. These network actions could not have been predicted from single-unit
recordings alone, indicating the utility of population based measures of simultaneously
recorded neuron discharge for better understanding the neural mechanisms underlying the
cognitive/behavioral effects of psychostimulants.
Methodological Considerations
Ventral CA1-subiculum stimulation in the home cage offers many advantages for initially
assessing the impact of low-dose MPH on PFC neuronal activity, including precise
quantification of PFC neuronal responses to afferent input under well-controlled conditions.
The hippocampus CA1-subiculum conveys behaviorally-important information to the PFC
(25,38). However, punctate stimulation of the CA1-subiculum is unlikely to provide much
behaviorally-relevant information. Nonetheless, the current observations demonstrate
significant facilitation of low-dose MPH on PFC neuron responsivity to afferent input from
this behaviorally-significant pathway. To better understand the functional significance of
MPH-induced alterations in PFC neuronal responsivity, ongoing studies in our laboratory have
extended the current approach to animals engaged in a PFC-dependent cognitive task (e.g.
working memory). Of particular interest in these studies is whether low-dose MPH uniformly
affects all task-related neuronal discharge within the PFC or whether MPH selectively affects
a subset of task-related discharge (e.g. delay-related activity).
Neurotransmitter bases for MPH-induced improvement in signal processing within the PFC
Previous microdialysis studies indicate that low-dose MPH preferentially increases NE and
DA efflux within the PFC (10). NE and DA exert a complicated array of actions on PFC
neuronal activity and PFC-dependent cognition that are concentration- and receptor-specific
(for reviews: 1,7,12). Available evidence indicates that postsynaptic α2-receptors (α2A)
facilitate, whereas α1-receptors impair PFC-dependent cognition (6). In contrast, D1 and D2
receptors exert inverted-U type modulatory actions on PFC-dependent cognition (41).
Consistent with these observations, MPH-induced improvement in working memory
performance is prevented by pretreatment with both a D1 and an α2-antagonist (7).
These behavioral actions of NE and DA receptors are paralleled by effects of these receptors
on PFC neuronal discharge activity (3–5,41,42). For example, in a saccade-based task of
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working memory, α2A-receptor stimulation strengthens delay-related activity of PFC neurons
for stimuli located in a neuron’s preferred direction (“signal”), whereas moderate D1 receptor
stimulation suppresses responses to stimuli located in non-preferred directions (“noise”; 3–
5,41,42). Therefore, we hypothesize that the ability of low-dose MPH to enhance responsivity
of PFC neurons at least involves stimulation of postsynaptic α2-receptors. Additional studies
have demonstrated that noradrenergic α1-receptor stimulation and high levels of D1 receptor
stimulation suppress delay-related discharge of PFC neurons (5,13). These latter observations
suggest that the ability of high dose MPH to suppress evoked discharge of PFC neurons likely
involves the actions of both α1-receptors and D1-receptors.
Summary
Despite the widespread use of low-doses of psychostimulants, the neural substrates underlying
the cognition-enhancing/behavioral-calming actions of these drugs are poorly understood. The
current observations indicate that cognition-enhancing doses of psychostimulants increase the
responsiveness of individual PFC neurons and modify representations of afferent input
distributed across ensembles of PFC neurons. Combined with previous neurochemical
observations (10), these observations indicate a unique sensitivity of the PFC to low-dose
psychostimulants and provide a perspective on low-dose psychostimulants alterations of
neuronal, ensemble, and cognitive functions that are likely critical components in the
therapeutic actions of low-dose psychostimulants in the treatment of ADHD.
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Example photomicrographs of electrode placements and representative peri-stimulus time
histograms (PSTH). A) 4X photomicrograph of the location of a recording microwire
implanted into the prelimbic area of the PFC in layer III (Arrow Tip). B) Stimulating electrode
placement within the CA1-subiculum region of the hippocampus (Arrow Tip; 10 X). C)
Placement of the electrode tip in the somatosensory cortex (4X). D) Example cumulative raster
and associated PSTH from three recorded neurons of the PFC before (Baseline) and after 0.5
mg/kg MPH. MPH administration produced four characteristic modulatory actions that
included: facilitation of stimulus-evoked excitatory responses (D1), gating of otherwise
subliminal afferent input (D2), suppression of excitatory responsiveness (D3), and facilitated
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stimulus-evoked inhibition (D1). X-axis = time (sec.) before and after stimulus presentation
(0.0 sec); histogram Y-axis = spikes/sec for a given time bin (0.005 sec); raster Y-axis = trial
number (top row, first trial). Inset waveforms indicate neural discrimination and recording
across experimental conditions. Inset bar (D1) indicates the inhibitory response window for
this example neuron. (PL, prelimbic; ACAd, anterior cingulate area, dorsal; DGcr, dentate
gyrus crest; CA1 region of the hippocampus; SUBv, ventral subiculum; SSp, primary
somatosensory cortex; ec, entorhinal cortex)
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Low-dose MPH improves performance measures of spatial working memory in an inverted-
U dose-dependent manner. Change in accuracy (% correct trials ± SEM) is plotted for vehicle
(VEH), 0.5 mg/kg MPH, and 2.0 mg/kg MPH administered IP. Performance was significantly
increased following 0.5 mg/kg MPH and significantly impaired following 2.0 mg/kg MPH.
*P < 0.05 vs. vehicle-treatment.
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The effects of low-dose MPH on the amount of desynchronized EEG activity. The percent of
time (mean ± SEM) animals exhibited desynchronized activity per 30-minute epoch is plotted
for baseline (30-minutes) and post-treatment (90-minutes) conditions. MPH significantly
increased time spent in a desynchronized EEG state only at the two highest doses tested (2.0
mg/kg and 15.0 mg/kg). Subjects used for each dose: Vehicle = 12, 0.25 mg/kg = 6, 0.5 mg/
kg = 14, 2.0 mg/kg = 14, 15.0 mg/kg = 3. *P < 0.05, ‡ P < 0.01 vs. vehicle-treatment.
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Modest changes in spontaneous discharge of PFC neurons following low- and high-dose MPH.
The percent change (± SEM) from baseline for the mean spontaneous discharge rates of
individual neurons recorded from the PFC is shown. Low-dose MPH produced a small increase
in spontaneous discharge rates 30–90 minutes post-treatment. This effect was largest for the
0.25 mg/kg dose, with the maximal increase observed at this dose in the 60–90-minute post-
treatment epoch. Between 0.5 mg/kg and 2.0 mg/kg, progressively higher doses had
progressively smaller effects on spontaneous discharge activity. In contrast, the highest dose
of MPH (15.0 mg/kg) significantly reduced spontaneous neuronal discharge. These effects
began to dissipate within 2 hours of MPH administration (data not shown). Scale is the same
as that used in Figure 5A to better permit comparison of drug effect on spontaneous vs.
excitatory evoked discharge. Numbers of neurons analyzed for each dose are listed in Table
1. *P < 0.05, ‡ P < 0.01 vs. vehicle-treatment.
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Effects of low-dose MPH on stimulus-evoked excitatory response properties. Plotted are the
percent change from baseline (± SEM) of the peak stimulus-evoked excitatory discharge (A)
and latency (B) of PFC neurons to CA1-subiculum stimulation. A) Increasing doses of MPH
produced an inverted-U facilitation/suppression of the peak stimulus-evoked excitatory
discharge. A maximal facilitatory effect (157% of baseline) was observed with the 0.5 mg/kg
dose. Further increases in MPH dose resulted in a reduction in this effect to near baseline levels
at the 2.0 mg/kg dose and well below baseline levels at the 15.0 mg/kg dose. B) The average
latency-to-peak discharge of PFC neurons following hippocampal stimulation was modestly
but significantly increased only following the highest dose of MPH tested. 1.0 mg/kg MPH
produced effects on both peak stimulus-evoked excitatory discharge and latency-to-peak
discharge that were intermediate to 0.5 mg/kg and 2.0 mg/kg and not significantly different
from vehicle (data not shown for clarity). In summary, low-dose MPH produced an inverted-
U shaped increase in the magnitude of excitatory evoked discharge of PFC neurons in the
absence of a change in response latency. Numbers of neurons analyzed for each dose are listed
in Table 1. *P < 0.05, ‡ P < 0.01 vs. vehicle-treatment.
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Inhibitory response magnitude and latency actions of low-dose MPH. The percent change from
baseline inhibition (A; baseline discharge - discharge during the inhibitory response) and the
percent change in duration of the inhibitory response (B) are shown (±SEM) following vehicle
or MPH. A) Increasing doses of MPH produced an inverted-U shaped facilitation of the
magnitude of inhibition (area under the peri-stimulus time histogram curve). In the 0–30 minute
post-treatment epoch, inhibition was maximally facilitated at the 0.5 mg/kg dose of MPH. In
contrast, the highest dose of MPH decreased inhibitory response magnitude. B) The duration
of stimulus-evoked inhibition was significantly reduced only following low doses of MPH
(0.25 mg/kg–0.5 g/kg). The effects of 1.0 mg/kg MPH were quantitatively similar to 2.0 mg/
kg on both magnitude of inhibition and duration of stimulus-evoked inhibition (data not shown
for clarity). In summary, low-dose MPH produced an inverted-U shaped increase in the
magnitude of inhibitory responses of PFC neurons while simultaneously decreasing the
duration of evoked inhibition. Numbers of neurons analyzed for each dose are listed in Table
1. *P < 0.05, ‡ P < 0.01 vs. vehicle-treatment.
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Distributed discharge patterns across PFC neural ensembles are altered by low-dose MPH.
Peri-stimulus time histograms (PSTHs) illustrate the response of the first (A) and second (B)
PC eigenfunction for a single simultaneously recorded ensemble of PFC neurons during
baseline conditions. PCA analysis was only conducted on subjects with a minimum of 10
simultaneously recorded neurons (range = 10–34). As in Fig. 1, PSTH X-axis represents time
(sec) before and after stimulus presentation (0.0 sec); the Y-axis indicates frequency for a given
time bin (0.005 sec). The magnitude of the response to CA1-subiculum stimulation for each
PC1 eigenfunction was calculated as peak height (Panel A grey line; a–b). Typically, PC2 was
biphasic and contained a trough of negative values. Therefore the magnitude of response for
each PC2 eigenfunction was calculated as the peak-to-trough height (Panel B grey line; a–b).
C) The response magnitude of PC1 was dose-dependently increased following 0.25 mg/kg–
0.5 mg/kg MPH and then returned to baseline levels following higher doses 1.0 mg/kg–15.0
mg/kg. D) PC2 demonstrated a dose-dependent reduction in magnitude following low-dose
MPH (0.25 mg/kg–0.5 mg/kg). Number of ensembles analyzed for each dose: Vehicle = 5,
0.25 mg/kg = 5, 0.5 mg/kg = 7, 1.0 mg/kg = 6, 15.0 mg/kg = 2. *P < 0.05, ‡ P < 0.01 vs.
baseline.
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Somatosensory BF cortex (BFC) neuron discharge properties are minimally affected by low-
dose MPH. Shown are the effects of 0.5 mg/kg MPH on spontaneous discharge (A), stimulus-
evoked discharge (B), or the latency-to-peak discharge (C) of BFC and PFC neurons (mean ±
SEM). PFC data are re-graphed from Figures 1 & 2 for comparison purposes. This dose of
MPH had no noticeable effects on these discharge properties of BFC neurons. This insensitivity
of BF neurons is in contrast to that seen in the PFC at this dose of MPH). Numbers of neurons
analyzed for each dose are listed in Table 1. *P < 0.05, ‡ P < 0.01 vs. baseline.
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Table 2
Distribution of Verified Single Units that Expressed “Gating” Following Vehicle or Methylphenidate.
BF Sensory Cortex Frontal Cortex
% Cells Gating Cell Count % Cells Gating Cell Count
Saline 26.3 % 80
0.25 mg/kg 29.1 % 55
0.5 mg/kg 8.8 % 34 35.1 % 94
1 mg/kg 18.2 % 11 32.6 % 43
2 mg/kg 22.4 % 49
15 mg/kg 40.0 % 25
Shown are the number and percentage of neurons displaying “gating” following treatment with vehicle or varying doses of MPH. The percentage of cells
that were “gated” following 0.5 mg/kg MPH was significantly higher (Chi-square; p=0.0187) relative to saline (vehicle) treatment.
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